Form 4: Apellis Pharmaceuticals Director Keli Walbert Reports Stock and Option Grants

Director Keli Walbert of Apellis Pharmaceuticals reported the acquisition of restricted stock units and stock options on January 8, 2025.

Summary

• Keli Walbert, a director at Apellis Pharmaceuticals, reported a transaction on January 8, 2025.
• The transaction involved the acquisition of 9,090 restricted stock units.
• These restricted stock units will fully vest on the first anniversary of the grant date, contingent on continued service as a director.
• Walbert also acquired 15,388 stock options with an exercise price of $33.
• These options vest over three years, with one-third vesting each year, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock and options to a director aligns their interests with the company's long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

This is a standard practice for publicly traded companies to grant equity compensation to directors and executives to align their interests with shareholders.

Comparison to Industry Standards

• Equity grants to directors are a common practice across the pharmaceutical industry.
• Vesting schedules of 1 to 3 years are typical for both restricted stock units and stock options.
• The specific number of shares and option grants will vary based on the company's size, performance, and compensation policies.
• Companies like Regeneron, Vertex, and Biogen also use similar equity-based compensation strategies for their directors.

Stakeholder Impact

• The equity grants to the director may be viewed positively by shareholders as it aligns interests.
• The vesting schedule encourages the director's continued service and commitment to the company.

Key Dates

Keywords

Apellis Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Equity Compensation, Form 4, Insider Trading